Is Dabigatran (Pradaxa) More Cost-Effective Than Warfarin in AF?

Dabigatran (Pradaxa), newly approved by the FDA to prevent stroke in patients with atrial fibrillation (AF), might turn out to be a cost-effective alternative to warfarin, according to an Annals of Internal Medicine study. Using data from the RE-LY trial, James Freeman and colleagues modeled the quality-adjusted survival and cost-effectiveness of dabigatran compared with high- or low-dose warfarin among adults older than 65 with AF. Cost was estimated based on current pricing in the U.K., where dabigatran has been approved since 2008.

The researchers found that high-dose dabigatran was the most efficacious and cost-effective strategy. Depending on pricing in the U.S., they conclude, the new drug might prove to be a more cost-effective option than warfarin. (Last week, CardioBrief reported that dabigatran will cost about $237/month at U.S. pharmacies.)

–by Amy Herman

This post is republished with permission from CardioExchange, a new website for cardiovascular healthcare professionals from the New England Journal of Medicine. CardioBrief readers who are healthcare professionals are invited to join the site.


  1. I have never used Pradaxa but my doctor gave me a discount drug card that I use on Warfarin. The Warfarin discount that I receive with the card really makes a difference. You can print a card from the MedicationCoupons website or you can contact them and ask them for a plastic card.

Speak Your Mind